FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	DC	20549
vvasilington,	D.O.	20070

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ı	UNIB APPRO	JVAL							
	OMB Number:	3235-0287							
	Estimated average burden								
	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Eaton Bruce  (Last) (First) (Middle)  C/O EDITAS MEDICINE, INC.						2. Issuer Name and Ticker or Trading Symbol     Editas Medicine, Inc. [ EDIT ]      3. Date of Earliest Transaction (Month/Day/Year)     08/09/2022								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title below)  EVP, CHIEF BUSINESS OFFICER					vner specify
(Street) CAMBR (City)	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person										
Table I - Non-Derivat  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea					2A. Deemed Execution Date,		, (ar) 8	3. Transaction Code (Instr. 8)		Amount (A) or Benef (A) or Disposed Of (D) (Instr. 3, 4 ar		d (A) or r. 3, 4 and	5. Amo Securi Benefi Owned Repor Transa		ount of ties cially I Following	Forn (D) c	m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common	Stock	Tal							293 posed of, converti			lly C		5,128 d		D			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if ar	Deemed cution Date, ny nth/Day/Year)	4. Transa Code 8)	(Instr.	5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr and 5	rative rities ired r osed )	Expiration Date (Month/Day/Year)			Amo Secu Undo Deriv Secu 3 and	Amount or Number of	t r		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

- 1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2022. The sale does not represent a discretionary trade by the Reporting Person.
- 2. This transaction was executed in multiple trades at prices ranging from \$18.0525 to \$18.61. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

/s/ Bruce Eaton

08/10/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.